Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer
September 30, 2021 2:05 amBy The ASCO Post Staff
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely … Read more